Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Cazzola

Showing results (621-630 of 645) with videos related to

Pageof 65
Sort By:
Leukemia Research|September 17, 2018
Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDSYasushi Miyazaki, Heinz Tuechler, Guillermo Sanz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2016
Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell TransplantationMatteo G Della Porta, Anna Gallì, Andrea Bacigalupo, et al.
Monaldi Archives for Chest Disease = Archivio Monaldi Per Le Malattie Del Torace|March 21, 2018
Inhalation therapy in the next decade: Determinants of adherence to treatment in asthma and COPDClaudio F Donner, Sandro Amaducci, Elena Bacci, et al.
Blood|November 10, 2022
Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasmsChristian Pecquet, Nicolas Papadopoulos, Thomas Balligand, et al.
Bone Marrow Transplantation|April 1, 2026
Defining remission and relapse after allogeneic hematopoietic cell transplantation in myelodysplastic/myeloproliferative neoplasms and optimization of transplantation outcomes: Recommendations from the EBMT practice harmonisation and guidelines committeeChristopher Armstrong, Kavita Raj, Giorgia Battipaglia, et al.
Blood Cancer Journal|March 15, 2018
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasmsValerio De Stefano, Alessandra Carobbio, Vincenzo Di Lazzaro, et al.
Blood|April 30, 2020
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDSLuca Malcovati, Kristen Stevenson, Elli Papaemmanuil, et al.
Blood|September 14, 2013
Clinical and biological implications of driver mutations in myelodysplastic syndromesElli Papaemmanuil, Moritz Gerstung, Luca Malcovati, et al.
The Lancet. Haematology|June 4, 2026
Donor cell-derived haematological neoplasms after allogeneic haematopoietic cell transplantation: recommendations from the EBMT Practice Harmonisation and Guidelines CommitteeCarmelo Gurnari, Chris Armstrong, Giorgia Battipaglia, et al.
Blood|February 19, 2025
Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMTCarmelo Gurnari, Marie Robin, Lionel Adès, et al.
Pageof 65

Showing results (621-630 of 645) with videos related to

Sort By:
Pageof 65
Leukemia Research|September 17, 2018
Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDSYasushi Miyazaki, Heinz Tuechler, Guillermo Sanz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2016
Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell TransplantationMatteo G Della Porta, Anna Gallì, Andrea Bacigalupo, et al.
Monaldi Archives for Chest Disease = Archivio Monaldi Per Le Malattie Del Torace|March 21, 2018
Inhalation therapy in the next decade: Determinants of adherence to treatment in asthma and COPDClaudio F Donner, Sandro Amaducci, Elena Bacci, et al.
Blood|November 10, 2022
Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasmsChristian Pecquet, Nicolas Papadopoulos, Thomas Balligand, et al.
Bone Marrow Transplantation|April 1, 2026
Defining remission and relapse after allogeneic hematopoietic cell transplantation in myelodysplastic/myeloproliferative neoplasms and optimization of transplantation outcomes: Recommendations from the EBMT practice harmonisation and guidelines committeeChristopher Armstrong, Kavita Raj, Giorgia Battipaglia, et al.
Blood Cancer Journal|March 15, 2018
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasmsValerio De Stefano, Alessandra Carobbio, Vincenzo Di Lazzaro, et al.
Blood|April 30, 2020
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDSLuca Malcovati, Kristen Stevenson, Elli Papaemmanuil, et al.
Blood|September 14, 2013
Clinical and biological implications of driver mutations in myelodysplastic syndromesElli Papaemmanuil, Moritz Gerstung, Luca Malcovati, et al.
The Lancet. Haematology|June 4, 2026
Donor cell-derived haematological neoplasms after allogeneic haematopoietic cell transplantation: recommendations from the EBMT Practice Harmonisation and Guidelines CommitteeCarmelo Gurnari, Chris Armstrong, Giorgia Battipaglia, et al.
Blood|February 19, 2025
Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMTCarmelo Gurnari, Marie Robin, Lionel Adès, et al.
Pageof 65